Loading...
Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells
Lu, Qingchun Xin, Mingyang Guo, Qian Rothberg, Brad S. Gamero, Ana M. Yang, Ling
Lu, Qingchun
Xin, Mingyang
Guo, Qian
Rothberg, Brad S.
Gamero, Ana M.
Yang, Ling
Citations
Altmetric:
Genre
Journal article
Date
2022-08-10
Advisor
Committee member
Group
Department
Medical Genetics and Molecular Biochemistry
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/ncrna8040061
Abstract
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with sorafenib increased the expression of TP53TG1 in HCC cells. Knockdown of TP53TG1 sensitized tumor cells to the antiproliferative effects of sorafenib. Furthermore, TP53TG1 knockdown had an additive inhibitory effect on HCC cell proliferation and migration in the presence of sorafenib. The combination of TP53TG1 knockdown and sorafenib drastically inhibited the activation of the ERK pathway. This work demonstrates that TP53TG1 deficiency enhances the efficacy of sorafenib in HCC. Combining TP53TG1 knockdown with sorafenib may be an optimal form of therapy for HCC treatment.
Description
Citation
Lu, Q.; Xin, M.; Guo, Q.; Rothberg, B.S.; Gamero, A.M.; Yang, L. Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells. Non-Coding RNA 2022, 8, 61. https://doi.org/10.3390/ncrna8040061
Citation to related work
MDPI
Has part
Non-Coding RNA (ncRNA), Vol. 8, Iss. 4
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu